Login to Your Account



Other News To Note


Monday, August 8, 2011
MolMed SpA, of Milan, Italy, signed an agreement with GlaxoSmithKline plc, of London, and will develop a production process for an investigational gene therapy for adenosine deaminase deficiency-severe combined immune deficiency, a rare, life-threatening disease that affects approximately 350 children worldwide. MolMed said it will receive as much as $7.78 million in revenue over a two-year period.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription